PTHLH and hypercalcemia disease: At the 8.0 nmol/kg dose of M‐PTH/PTHrP, frank hypercalcemia was observed at 8 hours after administration, and uCa at 0 to 8 hours, and uDpD at 0 to 24 hours increased significantly after the last administration (Figs. 4C,D, and S3B).